HRP20110169T1 - Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c - Google Patents
Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c Download PDFInfo
- Publication number
- HRP20110169T1 HRP20110169T1 HR20110169T HRP20110169T HRP20110169T1 HR P20110169 T1 HRP20110169 T1 HR P20110169T1 HR 20110169 T HR20110169 T HR 20110169T HR P20110169 T HRP20110169 T HR P20110169T HR P20110169 T1 HRP20110169 T1 HR P20110169T1
- Authority
- HR
- Croatia
- Prior art keywords
- meala
- treatment
- hcv
- etval
- ingredient
- Prior art date
Links
- 229960001265 ciclosporin Drugs 0.000 title abstract 2
- 208000005176 Hepatitis C Diseases 0.000 title 1
- 208000010710 hepatitis C virus infection Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 claims abstract 4
- 239000004615 ingredient Substances 0.000 claims 5
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 229950000038 interferon alfa Drugs 0.000 claims 2
- 239000012907 medicinal substance Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract 2
- 102000001493 Cyclophilins Human genes 0.000 abstract 1
- 108010068682 Cyclophilins Proteins 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Upotreba [D-MeAla]3-[EtVal]4-CsA, naznačena time, što se koristi za proizvodnju lijeka za liječenje HCV infekcije ili prevenciju rekurencije HCV. Patent sadrži još 5 patentnih zahtjeva.
Claims (6)
1. Upotreba [D-MeAla]3-[EtVal]4-CsA, naznačena time, što se koristi za proizvodnju lijeka za liječenje HCV infekcije ili prevenciju rekurencije HCV.
2. Upotreba prema zahtjevu 1, naznačena time, što se spomenuti [D-MeAla]3-[EtVal]4-CsA koji je prvi sastojak, primjenjuje zajedno ili se primjenjuje odvojeno, sa bar jednim drugim sastojkom koji je antivirusna ljekovita supstanca aktivna protiv HCV, odabrana iz grupe koja se sastoji od ribavirina i interferona alfa.
3. Farmaceutska smjesa koja uključuje [D-MeAla]3-[EtVaf]4-CsA kao prvi sastojak i bar jednu antivirusnu ljekovitu supstancu aktivnu protiv HCV kao drugi sastojak, naznačena time, što se spomenuti drugi sastojak bira iz grupe koja se sastoji od ribavirina i interferona alfa.
4. Farmaceutska smjesa prema zahtjevu 3, naznačena time, što dalje sadrži farmaceutski prihvatljivi nosač i, opcijski, razblaživač.
5. Farmaceutska smjesa prema bilo kojem od zahtjeva 3 ili 4, naznačena time, što se koristi za liječenje HCV infekcije ili prevenciju rekurencije HCV.
6. [D-MeAla]3-[EtVal]4-CsA, naznačen time, što se koristi za liječenje HCV infekcije ili prevenciju rekurencije HCV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2004003205 | 2004-10-01 | ||
| PCT/IB2005/002940 WO2006038088A1 (en) | 2004-10-01 | 2005-10-03 | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110169T1 true HRP20110169T1 (hr) | 2011-04-30 |
Family
ID=34959441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110169T HRP20110169T1 (hr) | 2004-10-01 | 2011-03-07 | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7439227B2 (hr) |
| EP (1) | EP1793844B1 (hr) |
| JP (1) | JP4892486B2 (hr) |
| KR (1) | KR101191833B1 (hr) |
| CN (1) | CN101056648B (hr) |
| AT (1) | ATE490778T1 (hr) |
| AU (1) | AU2005290984B2 (hr) |
| BR (1) | BRPI0515494A (hr) |
| CA (1) | CA2580448C (hr) |
| CY (1) | CY1114594T1 (hr) |
| DE (1) | DE602005025232D1 (hr) |
| DK (1) | DK1793844T3 (hr) |
| EA (1) | EA012650B1 (hr) |
| ES (1) | ES2357587T3 (hr) |
| GE (1) | GEP20104960B (hr) |
| HK (1) | HK1104236A1 (hr) |
| HR (1) | HRP20110169T1 (hr) |
| IL (1) | IL182362A0 (hr) |
| MA (1) | MA28950B1 (hr) |
| MX (1) | MX2007003387A (hr) |
| NZ (1) | NZ554412A (hr) |
| PL (1) | PL1793844T3 (hr) |
| PT (1) | PT1793844E (hr) |
| RS (1) | RS51614B (hr) |
| SG (1) | SG139750A1 (hr) |
| SI (1) | SI1793844T1 (hr) |
| TN (1) | TNSN07084A1 (hr) |
| UA (1) | UA88484C2 (hr) |
| WO (1) | WO2006038088A1 (hr) |
| ZA (1) | ZA200702610B (hr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| WO2006005610A1 (en) | 2004-07-14 | 2006-01-19 | Novartis Ag | Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv) |
| US7196161B2 (en) | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| JP4735861B2 (ja) | 2004-11-22 | 2011-07-27 | アステラス製薬株式会社 | 新規環状ペプチド化合物 |
| BRPI0519355A2 (pt) * | 2004-12-23 | 2009-01-20 | Novartis Ag | compostos para tratamento contra flaviviridae |
| AU2005322242B2 (en) * | 2004-12-23 | 2010-02-11 | Novartis Ag | Compositions for HCV treatment |
| CN101242842A (zh) * | 2005-06-17 | 2008-08-13 | 诺瓦提斯公司 | Sanglifehrin在hcv中的用途 |
| ATE498630T1 (de) | 2005-09-30 | 2011-03-15 | Scynexis Inc | Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion |
| NZ567262A (en) | 2005-09-30 | 2011-12-22 | Scynexis Inc | Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection |
| EP1957518B1 (en) | 2005-10-26 | 2015-12-09 | Astellas Pharma Inc. | New cyclic peptide compounds |
| NZ571826A (en) | 2006-04-11 | 2012-01-12 | Novartis Ag | HCV/HIV inhibitors and their uses |
| WO2007136759A2 (en) | 2006-05-19 | 2007-11-29 | Scynexis, Inc. | Method for the treatment and prevention of ocular disorders |
| CN101557819A (zh) * | 2006-10-12 | 2009-10-14 | 诺瓦提斯公司 | 修饰的环孢素的用途 |
| US7576057B2 (en) | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
| AU2008250254B2 (en) | 2007-05-02 | 2012-08-16 | Astellas Pharma Inc. | New cyclic peptide compounds |
| CA2700536A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| WO2009098533A1 (en) * | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy |
| WO2009148615A1 (en) * | 2008-06-06 | 2009-12-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
| US9090671B2 (en) | 2008-06-06 | 2015-07-28 | Scynexis, Inc. | Macrocyclic peptides |
| JP5758806B2 (ja) * | 2008-11-06 | 2015-08-05 | デビオ ルシェルシュ ファルマスーティク ソシエテ アノニムＤｅｂｉｏ Ｒｅｃｈｅｒｃｈｅ Ｐｈａｒｍａｃｅｕｔｉｑｕｅ Ｓｏｃｉｅｔｅ Ａｎｏｎｙｍｅ | シクロウンデカデプシペプチド化合物および医薬としてのその化合物の使用 |
| EP2376524B1 (en) | 2008-12-31 | 2017-03-15 | Cypralis Limited | Derivatives of cyclosporin a |
| NZ594755A (en) | 2009-01-30 | 2013-12-20 | Enanta Pharm Inc | Cyclosporin analogues for preventing or treating hepatitis c infection |
| US8481483B2 (en) | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US8349312B2 (en) | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
| US8685917B2 (en) | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
| WO2011070364A1 (en) | 2009-12-09 | 2011-06-16 | Scynexis, Inc. | Novel cyclic peptides |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| WO2011141891A1 (en) | 2010-05-12 | 2011-11-17 | Debio Recherche Pharmaceutique S.A. | Use of cycloundecadepsipeptide compounds |
| WO2012009715A2 (en) | 2010-07-16 | 2012-01-19 | S&T Global Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
| CN103153330B (zh) | 2010-08-12 | 2017-08-18 | 美国科技环球有限公司 | 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用 |
| CA2811700A1 (en) * | 2010-10-05 | 2012-04-12 | Novartis Ag | New treatments of hepatitis c virus infection |
| MX2013003945A (es) | 2010-10-08 | 2013-06-05 | Novartis Ag | Formulaciones de vitamina e como inhibidoras de sulfamida ns3. |
| BR112013013166A2 (pt) | 2010-11-30 | 2016-09-06 | Novartis Ag | tratamentos da infecção pelo vírus da hepatite c |
| US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
| JO3337B1 (ar) * | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| CN105749246A (zh) | 2011-03-31 | 2016-07-13 | 诺华股份有限公司 | 治疗丙肝病毒感染的阿拉泊韦 |
| JP2014509630A (ja) | 2011-04-01 | 2014-04-21 | ノバルティス アーゲー | Ｂ型肝炎ウイルス単独の感染症またはデルタ肝炎ウイルスとの複合感染症および付随する肝疾患の治療 |
| MA35029B1 (fr) | 2011-04-13 | 2014-04-03 | Novartis Ag | Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir |
| WO2013045460A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | Alisporivr for treatment of hepatis c virus infection |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| CN104284671A (zh) | 2012-05-07 | 2015-01-14 | 诺华股份有限公司 | 使用阿拉泊韦的药代动力学调节 |
| AR090964A1 (es) * | 2012-05-09 | 2014-12-17 | Novartis Ag | Proceso para la elaboracion de undecapeptidos ciclicos |
| WO2014085623A1 (en) | 2012-11-28 | 2014-06-05 | Enanta Pharmaceuticals, Inc. | Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues |
| US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
| WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| AU2014311346A1 (en) | 2013-08-26 | 2016-03-17 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C |
| WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
| WO2016073480A1 (en) | 2014-11-03 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Novel cyclosporin analogues for preventing or treating hepatitis c infection |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CN117624307A (zh) | 2017-05-12 | 2024-03-01 | 中外制药株式会社 | 用于制备环状有机化合物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757522B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| US6927208B1 (en) * | 1998-07-01 | 2005-08-09 | Debiopharm S.A. | Cyclosporin with improved activity profile |
| GB0320638D0 (en) * | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
-
2005
- 2005-10-03 DK DK05791430.1T patent/DK1793844T3/da active
- 2005-10-03 BR BRPI0515494-4A patent/BRPI0515494A/pt not_active IP Right Cessation
- 2005-10-03 EP EP05791430A patent/EP1793844B1/en active Active
- 2005-10-03 RS RS20110108A patent/RS51614B/en unknown
- 2005-10-03 UA UAA200704937A patent/UA88484C2/ru unknown
- 2005-10-03 CN CN2005800332843A patent/CN101056648B/zh not_active Expired - Fee Related
- 2005-10-03 SG SG200800480-6A patent/SG139750A1/en unknown
- 2005-10-03 GE GEAP200510037A patent/GEP20104960B/en unknown
- 2005-10-03 NZ NZ554412A patent/NZ554412A/en not_active IP Right Cessation
- 2005-10-03 PL PL05791430T patent/PL1793844T3/pl unknown
- 2005-10-03 KR KR1020077007285A patent/KR101191833B1/ko not_active IP Right Cessation
- 2005-10-03 ES ES05791430T patent/ES2357587T3/es active Active
- 2005-10-03 AT AT05791430T patent/ATE490778T1/de active
- 2005-10-03 DE DE602005025232T patent/DE602005025232D1/de active Active
- 2005-10-03 CA CA2580448A patent/CA2580448C/en not_active Expired - Fee Related
- 2005-10-03 PT PT05791430T patent/PT1793844E/pt unknown
- 2005-10-03 JP JP2007534110A patent/JP4892486B2/ja not_active Expired - Fee Related
- 2005-10-03 MX MX2007003387A patent/MX2007003387A/es active IP Right Grant
- 2005-10-03 EA EA200700725A patent/EA012650B1/ru not_active IP Right Cessation
- 2005-10-03 SI SI200531225T patent/SI1793844T1/sl unknown
- 2005-10-03 WO PCT/IB2005/002940 patent/WO2006038088A1/en active Application Filing
- 2005-10-03 AU AU2005290984A patent/AU2005290984B2/en not_active Ceased
-
2006
- 2006-04-12 US US11/406,800 patent/US7439227B2/en not_active Ceased
-
2007
- 2007-03-08 TN TNP2007000084A patent/TNSN07084A1/en unknown
- 2007-03-28 ZA ZA200702610A patent/ZA200702610B/xx unknown
- 2007-04-01 IL IL182362A patent/IL182362A0/en not_active IP Right Cessation
- 2007-04-27 MA MA29858A patent/MA28950B1/fr unknown
- 2007-11-21 HK HK07112681.2A patent/HK1104236A1/xx not_active IP Right Cessation
-
2008
- 2008-08-26 US US12/230,198 patent/US7772184B2/en not_active Expired - Fee Related
-
2010
- 2010-10-29 US US12/915,370 patent/USRE43371E1/en not_active Expired - Fee Related
-
2011
- 2011-03-07 HR HR20110169T patent/HRP20110169T1/hr unknown
- 2011-03-08 CY CY20111100263T patent/CY1114594T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110169T1 (hr) | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c | |
| HRP20090535T1 (hr) | Uporaba modificiranih ciklosporina za liječenje hcv poremećaja | |
| RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
| DE69129248T2 (de) | Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen | |
| BR0308137A (pt) | Formulações de droga de liberação constante contendo um peptìdeo veìculo | |
| WO2007059342A3 (en) | Random copolymer compositions for treating unwanted immune response | |
| HRP20180069T1 (hr) | Terapija za vitiligo | |
| WO2007078443A3 (en) | Methods of treating unwanted immune response with random copolymers | |
| HUP0400553A2 (hu) | Gyógyászati készítmények | |
| US20150258167A1 (en) | New Treatments of Hepatitis C Virus Infection | |
| RS50780B (sr) | Farmaceutske kompozicije na bazi nk2 antagonista za pedijatrijsku primenu | |
| EA200500672A1 (ru) | Содержащие альфузозин композиции с отсроченным высвобождением | |
| WO2004033479A3 (en) | Retroyclins: antiviral and antimicrobial peptides | |
| US20150139950A1 (en) | Alisporivir to treat hepatitis c virus infection | |
| WO2004096197A8 (en) | 5-aza-7-deazapurine nucleosides for treating flaviviridae | |
| US20160235808A1 (en) | Treatment of Hepatitis C Virus Infection with Alisporivir | |
| ATE284696T1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| Tan et al. | Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System: 1887 | |
| BR0215498A (pt) | Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes | |
| NZ600527A (en) | Antiviral compounds |